<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571710</url>
  </required_header>
  <id_info>
    <org_study_id>HR-BLTN-II-BTC</org_study_id>
    <nct_id>NCT04571710</nct_id>
  </id_info>
  <brief_title>A Trial of SHR1258 in Patients With Biliary Tract Cancer</brief_title>
  <official_title>A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with&#xD;
      advanced/ metastatic HER2-altered biliary tract cancers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (ORR) evaluated by Blinded Independent Radiology Review Committee (BIRC) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>from the first drug administration to within 28 days for the last SHR1258 dose</time_frame>
    <description>Adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Peak Plasma Concentration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: SHR1258 400mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1258</intervention_name>
    <description>Drug: SHR1258 400mg</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  enrollment into the study:&#xD;
&#xD;
               1. Signed and dated written informed consent which is approved by Institutional&#xD;
                  Review Board (IRB)/Ethics Committee (EC), willing and able to comply with&#xD;
                  scheduled treatment, all examinations at study visits, and other study&#xD;
                  procedures.&#xD;
&#xD;
               2. Male or female, ≥18 years old.&#xD;
&#xD;
               3. Histologically or cytologically confirmed (at a local laboratory) BTC&#xD;
&#xD;
               4. Received up to two prior regimen of systemic therapy for advanced disease,&#xD;
                  including 1 gemcitabine-containing regimen, and experienced disease progression&#xD;
                  after or developed intolerance to the most recent prior therapy.&#xD;
&#xD;
               5. Sufficient tumor tissue samples (archival or fresh biopsy samples) will be&#xD;
                  provided by all subjects prior to the administration of pyrotinib (for&#xD;
                  retrospective confirmation of HER2 alteration through a central laboratory if&#xD;
                  applicable).&#xD;
&#xD;
               6. Must have measureable disease per RECIST v1.1. The definition of CT or MRI&#xD;
                  measurable lesion as the target lesion: according to RECIST v1.1, the long&#xD;
                  diameter of such lesion should be ≥ 10 mm by the CT scan or the short diameter of&#xD;
                  enlarged lymph nodes ≥ 15 mm.&#xD;
&#xD;
               7. The laboratory test values must meet the functional level of important&#xD;
                  organs/systems meets&#xD;
&#xD;
               8. ECOG-PS (see Appendix 2): 0 - 1.&#xD;
&#xD;
               9. If subjects have active hepatitis B virus (HBV) infection: HBV- deoxyribonucleic&#xD;
                  acid (DNA) must be &lt; 500 IU/mL and are willing to receive antiviral therapy&#xD;
                  throughout the study; subjects with positive hepatitis C (HCV) ribonucleic acid&#xD;
                  (RNA) must receive antiviral therapy in accordance with the local standard&#xD;
                  treatment guideline and have ≤ CTCAE Grade 1 elevated hepatic function.&#xD;
&#xD;
              10. Women of childbearing potential (WOCBP) must have a serum pregnancy test within 7&#xD;
                  days before the first dose and the result is negative. WOCBP and male subjects&#xD;
                  whose partners are WOCBP must agree to use effective contraception method during&#xD;
                  the study period and within 8 weeks after the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Signed and dated written informed consent which is approved by Institutional Review&#xD;
             Board (IRB)/Ethics Committee (EC), willing and able to comply with scheduled&#xD;
             treatment, all examinations at study visits, and other study procedures.&#xD;
&#xD;
          2. Male or female, ≥18 years old.&#xD;
&#xD;
          3. Histologically or cytologically confirmed (at a local laboratory) BTC&#xD;
&#xD;
          4. Received up to two prior regimen of systemic therapy for advanced disease, including 1&#xD;
             gemcitabine-containing regimen, and experienced disease progression after or developed&#xD;
             intolerance to the most recent prior therapy.&#xD;
&#xD;
          5. Sufficient tumor tissue samples (archival or fresh biopsy samples) will be provided by&#xD;
             all subjects prior to the administration of pyrotinib (for retrospective confirmation&#xD;
             of HER2 alteration through a central laboratory if applicable).&#xD;
&#xD;
          6. Must have measureable disease per RECIST v1.1. The definition of CT or MRI measurable&#xD;
             lesion as the target lesion: according to RECIST v1.1, the long diameter of such&#xD;
             lesion should be ≥ 10 mm by the CT scan or the short diameter of enlarged lymph nodes&#xD;
             ≥ 15 mm.&#xD;
&#xD;
          7. The laboratory test values must meet the functional level of important organs/systems&#xD;
             meets&#xD;
&#xD;
          8. ECOG-PS (see Appendix 2): 0 - 1.&#xD;
&#xD;
          9. If subjects have active hepatitis B virus (HBV) infection: HBV- deoxyribonucleic acid&#xD;
             (DNA) must be &lt; 500 IU/mL and are willing to receive antiviral therapy throughout the&#xD;
             study; subjects with positive hepatitis C (HCV) ribonucleic acid (RNA) must receive&#xD;
             antiviral therapy in accordance with the local standard treatment guideline and have ≤&#xD;
             CTCAE Grade 1 elevated hepatic function.&#xD;
&#xD;
         10. Women of childbearing potential (WOCBP) must have a serum pregnancy test within 7 days&#xD;
             before the first dose and the result is negative. WOCBP and male subjects whose&#xD;
             partners are WOCBP must agree to use effective contraception method during the study&#xD;
             period and within 8 weeks after the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects presenting with any of the following will not be enrolled into the study:&#xD;
&#xD;
          1. Prior receipt of HER2-targeted therapy.&#xD;
&#xD;
          2. Concurrent anticancer therapy, other than the therapies being tested in this study.&#xD;
&#xD;
          3. Radiation therapy administered within 2 weeks of first dose of study treatment.&#xD;
&#xD;
          4. Laboratory values at screening outside the protocol-defined range.&#xD;
&#xD;
          5. Clinically significant or uncontrolled cardiac disease.&#xD;
&#xD;
          6. Target disease exclusion criteria:&#xD;
&#xD;
        1) Malignant tumors with other pathological types, such as mixed cancer, double primary&#xD;
        cancers.&#xD;
&#xD;
        2) Medical history of other active malignancies within last 5 years. 3) Subjects with&#xD;
        active central nervous system (CNS) metastases are excluded. Subjects with history or&#xD;
        evidence of current leptomeningeal metastases are excluded.&#xD;
&#xD;
        4) By the date of first dose of study treatment, the washout period of previous drug&#xD;
        treatment / medical intervention does not meet the following requirements 7. Medical&#xD;
        history exclusion criteria:&#xD;
&#xD;
          1. Severe cardiac disease&#xD;
&#xD;
          2. Prior to the first dose of study treatment, patients with the following conditions:&#xD;
             inability to swallow, chronic diarrhea, intestinal obstruction, gastrointestinal&#xD;
             perforation or gastrectomy, colitis or other diseases or special conditions that&#xD;
             affect drug administration and absorption.&#xD;
&#xD;
          3. Prior to the first dose of study treatment, patients with severe effusions with&#xD;
             clinical symptoms&#xD;
&#xD;
          4. Symptoms of severe infection or evidence for microbiological/viral diagnosis.&#xD;
&#xD;
          5. Congenital or acquired immunodeficiency (e.g., human immunodeficiency virus [HIV]&#xD;
             infection).&#xD;
&#xD;
        8. History of allergy to the study drugs or components. 9. Pregnancy or breastfeeding. 10.&#xD;
        Concomitant treatments exclusion criteria:&#xD;
&#xD;
          1. Within 2 weeks prior to the first dose of study treatment, or during the study period,&#xD;
             patients receive or are anticipated to receive continuous strong CYP3A4 inducers or&#xD;
             inhibitors, P-gp inhibitors.&#xD;
&#xD;
        11. Others:&#xD;
&#xD;
          1. Per investigator's judgment, other diseases or laboratory evidence that would cause&#xD;
             serious threats to the safety of the patients, or which are not in the best interest&#xD;
             of the patient to participate in the study are excluded&#xD;
&#xD;
          2. Per investigator's judgment, other situations that may confuse the study results or&#xD;
             would affect the subjects' ability to comply with study procedures are excluded, such&#xD;
             as alcoholism, drug abuse, criminal detention, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

